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ycophenolate mofetil (MMF) is a potent
immunosuppressive agent frequently used
to prevent acute graft rejection in solid
organ transplant recipients.1-3 Common adverse
effects of MMF include gastrointestinal disturbances,
leukopenia, and an increased susceptibility to viral
infections.4 Rarely, oral ulcerations may occur in
patients—especially solid organ transplant recipi-
ents—undergoing treatment with MMF.5-11 We pre-
sent 3 cases of MMF-induced oral ulcers in recipients
of kidney, liver, and lung transplants.
CASE 1
A 68-year-old man with a history of polycystic
kidney disease underwent bilateral cadaveric renal
transplantation and was started on an immunosup-
pressive regimen consisting of MMF (2 g/d) and
tacrolimus (16 mg/d). Eight months later, the patient
was admitted to the hospital with acute renal failure
and was noted to have multiple oral ulcers of
unknown duration associated with severe oral pain
and odynophagia. He denied a history of similar
lesions, recent fevers, or myalgias.
On examination, 3 major aphthous ulcers (11 mm
each) with surrounding erythema and petechiae
were present on his soft palate. Laboratory values
were significant for a white blood cell count of 3,700/
mm3, hemoglobin level of 9.4 g/dL, platelet count of
133,000/mm3, and creatinine level of 2.0 mg/dL.
Cultures of the oral lesions were negative for herpes
simplex virus (HSV) types 1 and 2, cytomegalovirus
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biopsy found nonspecific inflammatory changes on
hematoxylin-eosin (H&E) staining. Direct and indi-
rect immunofluorescence study findings were
normal.
MMF was subsequently discontinued. After
4 days, the patient’s oral ulcers decreased consider-
ably in size, and he reported a significant reduction
in his oral pain with an improved ability to eat and
drink. After 9 days, complete healing of the patient’s
ulcers was observed. The patient has since remained
off MMF with no recurrences of his ulcerations.
CASE 2
A 59-year-old woman with a history of cirrhosis
secondary to a1-antitrypsin deficiency received an
orthotopic liver transplantation and was started on
an immunosuppressive regimen consisting of MMF
(2 g/d), tacrolimus (6 mg/d), and prednisone
(2.5 mg/d). Five months later, the patient was
admitted to the hospital for evaluation of multiple
painful oral ulcerations and odynophagia of 6 weeks’
duration. She denied a history of similar lesions,
recent fevers, or myalgias.JAAD Case Reports 2015;1:261-3.
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Fig 1. Multiple aphthous ulcerations on the inside of the
lower lip (case 3). A, A 12-mm major aphthous ulceration.
B, A 5-mm minor aphthous ulceration.
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each) with surrounding erythema were present on
the inside of her lower lip, and one minor aphthous
ulcer (5 mm) was noted on her right buccal mucosa.
Laboratory values were significant for normal liver
function tests with a white blood cell count of 4,300/
mm3, hemoglobin level of 9.2 g/dL, and platelet
count of 112,000/mm3. Cultures of the oral lesions
were negative for HSV, CMV, and fungus. RPR and
HIV antibody testing results were nonreactive. Oral
biopsy found nonspecific inflammatory changes on
H&E staining. Direct and indirect immunofluores-
cence findings were normal.
MMF was subsequently discontinued. After
4 days, the size of the patient’s ulcers diminished
considerably with significant improvement in her
oral pain, and by 6 weeks, the ulcers had healed
completely. The patient has since remained off MMF
with no recurrences of her ulcerations.
CASE 3
A 65-year-old woman with a history of idiopathic
pulmonary fibrosis underwent single lung trans-
plantation. Postoperatively, she was started on an
immunosuppressive regimen of MMF (1 g/d), cyclo-
sporine (200 mg/d), and prednisone (40 mg/d). Ten
months later, the patient was hospitalized after
2 weeks of weakness and decreased oral intake in
the setting of multiple new ulcerations of her oral
mucosa.
The patient denied a history of oral ulcers, recent
fevers, or myalgias. She reported significant pain in
her mouth and had lost 5 pounds over the previous
2 weeks because of an inability to swallow or eat
food. She was initially prescribed oral fluconazole
and viscous lidocaine, but these treatments failed to
relieve her symptoms.
On examination, 2 minor aphthous ulcers (6 mm
and 8 mm) were present on her right buccal mucosa,
1 minor aphthous ulcer (3 mm) was observed
underneath her tongue, and 2 aphthous ulcers, 1major (12 mm) and 1 minor (5 mm), were noted on
the inside of her lower lip (Fig 1). Laboratory values
were significant for a white blood cell count of 3.7
cells/mm3, hemoglobin level of 7.0 g/dL, and platelet
count of 11,000 cells/mm3. Cultures of the oral
lesions were negative for HSV, CMV, and fungus.
RPR and HIVantibody results were nonreactive. Oral
biopsy found nonspecific inflammatory changes on
H&E staining. Direct and indirect immunofluores-
cence findings were normal.
MMF was subsequently discontinued. After
7 days, the patient’s ulcers diminished considerably
in size, and she reported a substantial decrease in her
oral pain. Long-term follow-up could not be ob-
tained, however, because the patient became criti-
cally ill during her hospitalization and died from
hospital-acquired pneumonia.
DISCUSSION
The differential diagnosis of oral mucosal ulcera-
tions in the immunocompromised patient includes
infections (most commonly HSV), hematologic dis-
orders, autoimmune and bullous diseases, and
malignancies.12 In our 3 patients, the workup for
all such causes was uniformly negative, making
MMF-induced aphthae a more likely explanation.
In contrast to certain immunosuppressive agents,
particularly mTOR inhibitors such as sirolimus—
which are well known to cause oral ulcers13—MMF
has only rarely been associated with such ulcers. To
date, 7 case reports have been published describing
this association, 6 of which involve solid organ
transplant recipients.5-11 In all cases, the develop-
ment of oral ulcers was not associated with any other
adverse effects of MMF (except for 1 case of
concomitant perianal ulcers6), and regression of the
ulcers occurred within 7 to 10 days after discontin-
uation of MMF. By comparison, the reported interval
between the initiation of MMF therapy and the
formation of oral ulcers varies greatly, ranging from
1 week to 3 years. Notably, each of our three cases
mirrored this pattern of clinical findings: oral ulcers
developed within five to ten months of beginning
MMF therapy, presented without the emergence of
other adverse effects of MMF, and demonstrated
dramatic improvement four to seven days after
discontinuation of the drug.
Two mechanisms have been proposed to explain
the association between MMF and oral ulcers. The
first, and perhaps most likely, is a direct MMF-
induced cytotoxicity on oralmucosa. This hypothesis
is substantiated by the observation that in each
reported case of MMF-associated ulcers (including
the 3 published in this case series), both the size of the
ulcers and their associated pain and odynophagia
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tinuation of MMF therapy, suggesting a direct toxi-
genic relationship between the 2. Moreover, a case
report published by Miquel et al11 describing the
association of oral ulcers andmycophenolate sodium
(an enteric-coated, delayed-release formulation of
MMF) in a patient with systemic lupus erythematosus
documented the abrupt recurrence of the patient’s
oral ulcers several days after she was rechallenged
with mycophenolate sodium, further corroborating
the direct toxicity hypothesis.
Second, some have posited that the association
between MMF and oral ulcers may be owing to
viral infection secondary to immunosuppression.
Although some empirical evidence for this hypoth-
esis does exist, all viral cultures reported in the
literature, including our cases, have been negative,
and attempts to discontinue other immunosuppres-
sive agents before discontinuing MMF have not
successfully resolved patients’ oral lesions.8 The
association between MMF-induced ulcers and viral
infection is thus tenuous at best.
Regardless of the mechanism underlying mucosal
damage, it is clear that an association exists between
MMF and oral ulcers. In particular, recipients of solid
organ transplants seem to be especially susceptible to
the development of such ulcers. A possible explana-
tion for the increased incidence of MMF-induced
ulcers in these patients is that plasma levels of MMF
have been found to increase dramatically when MMF
is combined with certain additional immunosuppres-
sive drugs, most notably cyclosporine.14 In patients
maintained on both medications—a frequent combi-
nation in transplant recipients—plasma drug concen-
trations of MMF may thus be much higher than
initially anticipated, predisposing these patients to
the development of oral ulcers. This explanation may
also underlie the increased incidence of oral ulcers in
transplant patients on a combination of MMF and
sirolimus compared with those on MMF and tacroli-
mus.10 Although plasma levels of MMF are not
routinely assessed in hospitalized patients and are
thus unfortunately not reported in any of the pub-
lished cases series (including this one), limited
pharmacologic data do support the assertion that
elevated plasma levels of MMF may play a role in the
development of oral ulcers in transplant recipients.
MMF levels may therefore represent a useful adjunc-
tive laboratory test to help confirm the diagnosis in
patients with suspected MMF-induced oral ulcers.
Although the precise mechanism has yet to be
elucidated, an association exists between MMF andthe development of oral ulcers, especially among
solid organ transplant recipients. MMF-induced
aphthae should thus be added to the differential
diagnosis of oral ulcerations in the immuno-
compromised host, and discontinuation of MMF
should be considered in a patient with refractory
oral ulcers and a negative workup for other
etiologies.REFERENCES
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